Wegovy 7.2mg Explained: A Complete Guide to the New Dose
New Wegovy Pill Is Now Available
The Wegovy pill has been approved in the UK and is available to buy at The Independent Pharmacy, subject to eligibility.
As of January 2026, the maximum weekly dose of Wegovy has increased from 2.4mg to 7.2mg, following approval by the Medicines and Healthcare products Regulatory Agency (MHRA).
Studies suggest that this newly approved dosage may be more effective for further weight reduction among adults with obesity.
Previously, the 7.2mg dose required three separate 2.4mg injections. As of 1st June 2026, the Wegovy 7.2mg dose is available as one single injection. The medication itself hasn’t changed. You’re still receiving the same weekly 7.2mg dose of semaglutide, but it can now be administered using a single-dose pen rather than 3 separate injections of 2.4mg.
This higher dose of Wegovy 7.2mg is now available through UK-licensed prescribing services, subject to clinical assessment.
In this guide, we outline the effectiveness of the higher dosage, explain how it’s administered, and provide advice on safely increasing your dosage or switching from a different treatment.
What Is the New Wegovy 7.2mg Dose?
Wegovy 7.2mg is the newly approved, higher-dose version of the semaglutide weight-loss treatment manufactured by Novo Nordisk.
Clinical trials of Wegovy 7.2mg have shown that, on average, patients can lose almost 21% of their body weight in 72 weeks, offering results similar to those achieved with the maximum dose of the leading weight-loss and type 2 diabetes treatment, Mounjaro.
Wegovy works by mimicking GLP-1, a naturally occurring hormone involved in appetite regulation. This can help reduce hunger and cravings while increasing feelings of fullness.
When Will the New Wegovy 7.2mg Dose Be Available in the UK?
The higher Wegovy dosage license was approved on 12 January 2026 and is now available through UK-licensed prescribing services.
Wegovy 7.2mg is available on a prescription-only basis and under medical supervision. Following a clinical assessment, patients can begin a treatment plan tailored to their weight loss and health goals.
How Effective Is the New Wegovy 7.2mg Dose?
In the 72-week STEP UP trial, people taking the higher 7.2mg dose of semaglutide lost more weight on average than those taking the 2.4mg dose or a placebo.
Participants were randomly assigned to each group, and neither they nor the researchers knew which treatment anyone was receiving. This helps ensure the results are fair and unbiased.
On average, participants lost:
- 20.7% of their body weight with semaglutide 7.2mg
- 17.5% with semaglutide 2.4mg
- 2.4% with placebo, which looks the same as the treatment but contains no active ingredients
Who Is Wegovy 7.2mg Suitable For?
Pending a clinical assessment, Wegovy 7.2mg is a suitable treatment for patients aged 18 years and above who meet any of the following criteria:
- A BMI of 30 or above
- A BMI of 27 or above alongside a weight-related health condition such as prediabetes, high blood pressure or type 2 diabetes
It’s important to note that this treatment is most effective when combined with a balanced diet and regular physical activity.
How can I Switch to the New Wegovy 7.2mg Dose?
If you’re considering moving to the 7.2mg dose, you’ll need to have been using Wegovy 2.4mg for at least four weeks. There are no additional dose increases between 2.4mg and 7.2mg, so eligible patients can move directly to the higher dose following a clinical assessment.
If you’re new to Wegovy, treatment will begin at the lowest dose and be increased gradually until the appropriate maintenance dose is reached.
Before recommending a dose increase, a pharmacist will review your progress, any side effects you have experienced, and whether the 7.2mg dose is appropriate for you.
Wegovy Weight Loss Injections
Wegovy is a specially formulated medication that’s clinically proven to aid weight loss. Taken as a weekly injection, it could help to control your appetite and prevent you eating more than you need to.
How To Take the Wegovy 7.2mg Dose
Wegovy 7.2mg Usage Instructions
Wegovy 7.2mg is taken once weekly using the dedicated 7.2mg pen. Unlike the 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg pens, the 7.2mg pen already has the needle attached, which is hidden and only retracts when you press the pen firmly against your skin.
The 7.2mg dose is pre-set, so you don’t need to dial the dose and you don’t need to prime the pen.
Step 1: Choose the injection site. Either the:
- Stomach
- Thigh
- Upper arm (if someone else is injecting you)
To reduce the risk of irritation, it’s recommended to rotate injection sites each week.
Step 2: Clean and dry the injection site
Step 3: Pull off the cap of the pen
Step 4: Place the pen where you want to inject it and press it firmly into your skin at a 90° angle. Keep pressing for 5-10 seconds. Listen for 2 clicks. You should see the yellow bar moving down the side of the pen, when it stops, the dose is complete.
Step 5: Slowly lift the pen straight off your skin and put the entire pen into your sharps bin. The needle cover will lock when the pen is removed from your skin.
Note: There may be a drop of blood or a small drop of medicine on the skin, this is normal. If there’s more than a drop, get in touch with our clinical team to check everything is working as it should.
You should:
- Take the dose on the same day each week where possible
- Follow the instructions provided with your pen and prescription
Detailed instructions can also be found in the Wegovy Patient Information Leaflet.
What Are the Possible Side Effects of Wegovy 7.2mg?
Taking 7.2mg of Wegovy is associated with side effects similar to those seen at lower doses.
Side effects normally affect the digestive system, with around 1 in 10 patients commonly experiencing:
- Headaches
- Nausea
- Vomiting
- Diarrhoea
- Fatigue
- Constipation
- Stomach pain
If you are feeling the side effects, you could try The Independent Pharmacy's unique GLP-1 Side Effects Treatment Pack. The three products will help you manage the common side effects you may experience.
Where and When Can I Purchase the New Wegovy 7.2mg Dose in the UK?
Wegovy 7.2mg has been approved for use in the UK and can be prescribed through UK-licensed prescribing services, such as The Independent Pharmacy, following a clinical assessment.
Before any change in dose is recommended, a qualified healthcare professional will review your medical history, current treatment and any pre-existing health conditions to ensure the higher dose is safe and appropriate for you.
Wegovy 7.2mg FAQs
Why is Novo Nordisk introducing the new 7.2mg dose?
Novo Nordisk submitted the higher 7.2mg dose to regulators because clinical trial data showed greater weight loss compared to the 2.4mg dose, offering another treatment option for people with obesity.
How much does Wegovy 7.2mg cost?
The price of Wegovy 7.2mg will depend on the pharmacy supplying it.
Can I switch from Wegovy 2.4mg to the 7.2mg dose?
Yes. If you've been using the 2.4mg dose of Wegovy for at least 4 weeks, you may be able to increase to 7.2mg following a clinical assessment. There are no additional doses between 2.4mg and 7.2mg, so eligible patients can move directly to the higher dose.
Do not adjust your dosage without consulting your prescriber.
Can I switch to Wegovy 7.2mg from a different treatment?
Yes. In some cases, you may be able to switch from another weight loss treatment, but this requires careful planning and consultation. Our clinicians will consider factors such as your current medication, any side effects and your overall health before recommending any change.
Can I get Wegovy 7.2mg on the NHS?
No. Wegovy 7.2mg is not yet available on the NHS. While the treatment has been approved by the MHRA, it’s pending approval and licensing by NICE at the time of writing.
How much weight could I lose with Wegovy 7.2mg?
The STEP UP clinical trial reports a weight loss of just over 20% after 72 weeks; however, this may not be the case for all users.
Wegovy 7.2mg represents a significant step forward in medical weight management, providing a structured, clinically guided approach for patients who need additional support to achieve sustainable weight loss outcomes.
Understanding how this dose works, who it’s suitable for and how to use it safely is essential for long-term success. That’s why personalised advice matters.
Have a question?
If you’d like more information about Wegovy, your treatment options, or an existing order, our customer service team can help. Complete the contact form and we’ll respond within one business day.
Ready to Find Out If Wegovy Is Right For You?
Talk to one of our clinicians. We’ll take a full picture of your health, discuss your goals, and help you understand what to expect, honestly and without pressure.
"Excellent"
How Does the Recent Wegovy Storage Update Affect Me?
Following a recent update from the MHRA, Wegovy can now be delivered at temperatures below 30°C for up to 48 hours.
This update relates to how Wegovy is transported to you and does not change how you should store your medication at home.
We are reviewing what this means for our packaging and delivery processes to ensure everything remains safe and in line with guidance. In the meantime, please continue to follow the storage instructions provided with your medication. If anything changes, we’ll update our guidance and let you know.
Sources:
- GOV.UK. GLP-1 medicines for weight loss and diabetes: what you need to know. London: UK Government; [cited 2026 Jan]. Available from: https://www.gov.uk
- Wharton S, Freitas P, Hjelmesæth J, Kabisch M, Kandler K, Lingvay I, et al. Efficacy and safety of semaglutide 7.2mg in adults with obesity: the STEP UP trial. Lancet Diabetes Endocrinol. 2025;13(11):949–963. Available from: https://diabetesjournals.org/diabetes/article/74/Supplement_1/1966-LB/158768/1966-LB-Efficacy-and-Safety-of-Semaglutide-7-2-mg
- Electronic Medicines Compendium (eMC). Wegovy® FlexTouch® 2.4 mg solution for injection: patient information leaflet. Datapharm; [cited 2026 Jan]. Available from: https://www.medicines.org.uk
- Diabetes UK. What is Wegovy? Uses, how it works and side effects. London: Diabetes UK; [cited 2026 Jan]. Available from: https://www.diabetes.org.uk
- Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7.2mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949–963. Available from: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00226-8/abstract
Read our Wegovy guides
Our expert clinical team have published a range of reviewed and clinically-sourced information on Wegovy to ensure our patients have all the information they need on their weight loss journey.
